Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Free Cash Flow (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Free Cash Flow data on record, last reported at -$36.6 million in Q4 2025.

  • For Q4 2025, Free Cash Flow fell 34.05% year-over-year to -$36.6 million; the TTM value through Dec 2025 reached $702.3 million, up 751.77%, while the annual FY2025 figure was $702.3 million, 751.77% up from the prior year.
  • Free Cash Flow reached -$36.6 million in Q4 2025 per PTCT's latest filing, up from -$69.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $868.4 million in Q1 2025 and bottomed at -$174.6 million in Q4 2022.
  • Average Free Cash Flow over 5 years is -$13.0 million, with a median of -$58.3 million recorded in 2021.
  • Peak YoY movement for Free Cash Flow: tumbled 1548.94% in 2024, then surged 1319.55% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$77.6 million in 2021, then tumbled by 125.08% to -$174.6 million in 2022, then skyrocketed by 39.37% to -$105.9 million in 2023, then soared by 74.17% to -$27.3 million in 2024, then tumbled by 34.05% to -$36.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$36.6 million in Q4 2025, -$69.7 million in Q3 2025, and -$59.6 million in Q2 2025.